ArticleRenal failure2026
Proteomic Mendelian randomization and machine learning reveal causal plasma biomarkers in cardiorenal comorbidity.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) significantly increases the risk of coronary artery disease (CAD), but the causal plasma proteins linking these conditions are poorly understood. This study aimed to identify genetically validated plasma biomarkers and therapeutic targets for this cardiorenal link.
methodsWe integrated multi-omics data using a Mendelian randomization (MR) framework. The analysis incorporated protein quantitative trait loci (pQTL) data and gene expression datasets for CAD and CKD. A mediation MR approach identified plasma proteins that genetically mediate the causal pathway from CKD to CAD. Machine learning, including Boruta feature selection and support vector machine (SVM) modeling, was used to refine a diagnostic panel from the candidate proteins.
resultsAnalysis identified six key causal mediator proteins: LIMA1, PLCG1, and PZP (which promoted CAD risk in CKD), along with HGF, SERPINE2, and TXNDC15 (which exerted protective effects). A diagnostic panel based on these proteins showed strong predictive performance. Functional analysis indicated these proteins converge on lipid-inflammation pathways and modulate immune responses. Molecular docking suggested imatinib as a high-affinity binder to HGF, indicating drug repurposing potential.
conclusionThis study defines a genetically anchored plasma protein panel that mechanistically links CKD to CAD
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.